glp 1 non injectable injection A new study is looking at a possible link between certain diabetes Oral Semaglutide Shows Promise in

More than 250 clinicians signed a letter (PDF) to the Senate HELP Committee expressing concern about the lack of patient access to novel non-insulin diabetes and weight loss medications due to exorbitant prices set by manufacturers

The Bottom Line: Congress should codify and expand on the Trump administrations most-favored-nation policy

If gastrointestinal discomfort (including bloating, cramps, diarrhea, or other digestive upset) or other sensitivity is experienced stop taking the product immediately

Regular follow-ups, either in-person or via telehealth, allow for real-time monitoring and dose adjustments

GLP-1s, a class of drugs used to treat type 2 diabetes, obesity, cardiovascular disease, and other conditions, have exploded in popularity in recent years due to their demonstrated effectiveness, but are often not covered by insurance, particularly for the treatment of obesity